Objective: To accurately estimate the global prevalence of non-tuberculous mycobacteria (NTM) in adults with non-cystic fibrosis (non-CF) bronchiectasis and to determine the proportion of NTM species and subspecies in clinical patients from 2006 to 2021.
Design: Systematic review and meta-analysis using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Data Sources: Medline, Embase, Cochrane Library and Web of Science were searched for articles published between 2006 and 2021.
Eligibility Criteria For Selecting Studies: We included all the prospective or retrospective studies without language restrictions and all patients were adults (≥18 years of age) with non-CF bronchiectasis. The studies estimated the effect size of the prevalence of NTM with a sample size ≥40, and patients were registered in and after 2006.
Data Extraction And Synthesis: Two reviewers screened the titles, abstracts and full texts independently. Relevant information was extracted and curated into tables. Risk of bias was evaluated following the Cochrane Collaboration's tool. Meta-analysis was performed with software R Statistics V.3.6.3 using random effect model with 95% CI. I index and Q statistics were calculated to assess the heterogeneity, and mixed-effects meta-regression analyses were performed to identify the sources of heterogeneity. The proportions of NTM subspecies were examined using Shapiro-Wilk normality test in R.
Results: Of all the 2014 studies yielded, 24 met the inclusion criteria. Of these, 14 were identified to be randomised controlled studies and included for an accurate estimation. The global prevalence of NTM in adults with non-CF bronchiectasis from 2006 to 2021 was estimated to be approximately 10%, with great variations primarily due to geographical location. complex was the most common subspecies, followed by and .
Conclusions: The prevalence of NTM in adults with non-CF bronchiectasis has been on the rise and the most common subspecies changed greatly in recent years. More cohort studies should be done in many countries and regions for future estimates.
Prospero Registration Number: CRD42020168473.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345037 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2021-055672 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reconsidering the Diagnosis: Abnormal Sweat Chloride Tests in Non-CF Bronchiectasis.
Pediatr Pulmonol
January 2025
Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Virginia, Charlottesville, Virginia, USA.
Introduction: While the diagnosis of cystic fibrosis (CF) is often straightforward and reliant on correlation between genetic testing and clinical signs and symptoms, there is a subset where the distinction is not nearly as clearcut. This has previously been reported in patients identified through newborn screening but not meeting full CF diagnostic criteria, earning the label of CF Screen Positive, Inconclusive Diagnosis (CFSPID) instead. A homologous diagnostic category in adults is named CF Transmembrane Conductance Regulator-Related Disorder (CFTR-RD).
View Article and Find Full Text PDFDisarming the cavalry: targeting neutrophils to limit collateral damage in non-CF bronchiectasis.
Eur Respir J
January 2025
Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Lung function trajectories in children with early diagnosis of non-cystic fibrosis bronchiectasis: a retrospective observational study.
Ital J Pediatr
November 2024
Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy.
Background: Non-cystic fibrosis (non-CF) bronchiectasis (BE) is defined as a clinical syndrome of recurrent, persistent wet cough and abnormal bronchial dilatation on chest High Resolution Computed Tomography (HRCT) scans. The aims of this study were to characterize the pattern of the trajectories of lung function parameters and to consider the relationship between the lung function and radiological severity according to the modified Reiff score.
Methods: The study retrospectively considered 86 children (46.
Protein phosphatase 2A activators under investigation for smoking-related chronic obstructive pulmonary disease and related disorders.
Expert Opin Investig Drugs
November 2024
Faculty of Medicine, 3rd Department, University of Medicine and Pharmacy, Carol Davila Bucuresti, Bucuresti, Romania.
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) and other chronic respiratory disorders like cystic fibrosis and alpha-one antitrypsin deficiency share inflammation and progression characteristics, prompting investigations into anti-inflammatory treatments.
- A systematic review of studies from 2000 onward focuses on the role of protein phosphatase 2A (PP2A) in inflammation, its suppression by smoking, and the potential benefits of its activation in treating COPD.
- Experts suggest that activating PP2A could be a viable therapy for COPD and related disorders, highlighting promising avenues like repurposing metformin and inhalation methods, although most evidence is still in the experimental stage.
Article Synopsis
- - Chronic airway inflammation is a major factor in bronchiectasis, influenced by neutrophils that release harmful proteins called neutrophil serine proteases (NSPs) in both cystic fibrosis (CF) and non-CF conditions.
- - There’s an imbalance between NSPs and their counteracting proteins in patients with CF and non-CF bronchiectasis, but effective treatments targeting NSPs are currently lacking.
- - Even with new CFTR modulator therapies improving outcomes for cystic fibrosis patients, airway inflammation remains a problem, highlighting the need for new treatment strategies focused on managing neutrophilic inflammation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!